We traveled to Long Island, New York, for a State of the Science Summit™ on Breast Cancer, which featured insights from the NYU Langone’s Perlmutter Cancer Center faculty.

We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.

We traveled to Philadelphia, Pennsylvania, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the University of Pennsylvania faculty.

We traveled to Chicago, Illinois, for a State of the Science Summit™ on Lung Cancer, which featured insights from the University of Chicago faculty.

We traveled to Raleigh, North Carolina, for a State of the Science Summit™ on Breast Cancer, which featured insights from the Duke Cancer Institute faculty.

We traveled to Salt Lake City, Utah, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from the University of Utah and Intermountain Healthcare.

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.

We traveled to Seattle, Washington, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Seattle Cancer Care Alliance faculty.

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.

We traveled to Pasadena, California, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from City of Hope faculty.

We traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty.

We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Genitourinary Cancers, which featured insights from the faculty from the Dana-Farber Cancer Institute.

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from the Medical College of Wisconsin.

We traveled to Lexington, Kentucky, for a State of the Science Summit™ on Neuroendocrine Tumors, which featured insights from the faculty from University of Kentucky Markey Cancer Center.

We traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer, which featured insights from the faculty from City of Hope.

We traveled to Dallas, Texas, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from Baylor Scott and White Health System faculty.

We traveled to Tampa, Florida, for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from the faculty from Moffitt Cancer Center and Mayo Clinic.

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from Dana-Farber Cancer Institute.

We traveled to Dallas, Texas, for a State of the Science Summit™ on Breast Cancer, where faculty relayed the prognostic value of genomic assays in breast cancer and the scope of established and ensuing treatment approaches for those with early-stage and advanced disease.

We recently traveled to Charlotte, North Carolina, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured expert insight on treatment approaches across metastatic colorectal cancer, locally advanced and metastatic pancreatic cancer, advanced hepatocellular carcinoma, neuroendocrine tumors, and advanced gastric cancer.

We traveled to New York City, New York, for a State of the Science Summit™ on Ovarian Cancer, where faculty shared their insight on the various surgical and medical treatment modalities in advanced ovarian cancer, as well as investigational interventions that may further define standards of care.

We traveled to Durham, North Caroline, for a State of the Science Summit™ on Gastrointestinal Malignancies, where faculty shared key updates from the 2019 Gastrointestinal Symposium.

We traveled to Chicago, Illinois, for a State of the Science Summit™ on Breast Cancer, where faculty provided a comprehensive look into present and potentially future standards of care in early-stage and advanced breast cancer subtypes.

We traveled to Washington, D.C., for a State of the Science Summit™ on Gastrointestinal Cancer, which focused on the clinically diverse and steadily expanding therapeutic armamentariums for patients with gastrointestinal malignancies.

We traveled to Houston, Texas, for a State of the Science Summit™ on Gastrointestinal Cancer, which focused on the rapidly evolving landscapes of colorectal cancer, gastric/GEJ cancer, pancreatic cancer, neuroendocrine tumors, and hepatocellular carcinoma.

We traveled to Nashville, Tennessee, for a State of the Science Summit™ on Breast Cancer, which focused on some of the practice-changing updates that have been occurring in the field.

We traveled to Pasadena, California, for a State of the Science Summit™ on Genitourinary Malignancies, which focused on the rapidly evolving landscapes of kidney, bladder, and prostate cancer.

We traveled to NewYork City, New York, for a State of the Science Summit™ on Breast Cancer, which focused on the latest updates in the rapidly evolving paradigms of triple-negative breast cancer, HER2-positive breast cancer, hormone receptor-positive, HER2-negative disease, and more.

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, which focused on the facets of genetic testing in ovarian cancer, surgical options available for patients with newly diagnosed disease, and emerging strategies for the treatment of patients with uterine sarcomas, among other key topics.